NewAmsterdam Pharma Co N.V. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NewAmsterdam received European Commission approval in September 2026 for Ubeslo (obicetrapib 10mg monotherapy) and Evlarco (obicetrapib 10mg + ezetimibe 10mg fixed-dose combination)—the first worldwide regulatory approval of obicetrapib. Under the Menarini licensing agreement, NewAmsterdam receives tiered double-digit percentage royalties (low double-digits to mid-twenties) on European net sales plus up to €817 million in clinical/regulatory/commercial milestones. The company reported Q3 2026 revenue of $19.2M (vs. $0.3M in Q3 2025), primarily from Menarini milestone recognition; cash position of $643.1M (down from $728.9M at year-end 2025); and a net loss of $17.4M (vs. $72.0M loss in Q3 2025). PREVAIL cardiovascular outcomes trial (9,500+ enrolled) interim analysis is planned for 4Q2026 with results expected 1Q2027. The company also initiated SPINOZA Phase 2b trial in preclinical Alzheimer's disease (approximately 400 participants).
Why this rating
First regulatory approval is pivotal milestone for clinical-stage biotech; €817M milestone potential and royalty stream material to $1.3B market cap; PREVAIL readout imminent and transformational. Moderate cash runway concerns offset gains.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.